The closing price of Collegium Pharmaceutical Inc (NASDAQ: COLL) was $39.66 for the day, up 2.24% from the previous closing price of $38.79. In other words, the price has increased by $+0.87 from its previous closing price. On the day, 584173 shares were traded.
Ratios:
Our analysis of COLL’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.62. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.17. In the meantime, Its Debt-to-Equity ratio is 3.45 whereas as Long-Term Debt/Eq ratio is at 2.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on January 04, 2024, Downgraded its rating to Hold and sets its target price to $37 from $30 previously.
On August 25, 2023, Needham reiterated its Buy rating and also lowered its target price recommendation from $35 to $36.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 29 ’24 when Smith Thomas B sold 995 shares for $36.76 per share. The transaction valued at 36,580 led to the insider holds 63,409 shares of the business.
Dreyer Scott sold 10,000 shares of COLL for $364,270 on Feb 26 ’24. The EVP & Chief Commercial Officer now owns 138,918 shares after completing the transaction at $36.43 per share. On Jan 16 ’24, another insider, Dreyer Scott, who serves as the EVP & Chief Commercial Officer of the company, sold 23,560 shares for $32.28 each. As a result, the insider received 760,519 and left with 111,322 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COLL now has a Market Capitalization of 1.27B and an Enterprise Value of 1.63B. As of this moment, Collegium’s Price-to-Earnings (P/E) ratio for their current fiscal year is 33.48, and their Forward P/E ratio for the next fiscal year is 5.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 60.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.24 while its Price-to-Book (P/B) ratio in mrq is 6.47. Its current Enterprise Value per Revenue stands at 2.88 whereas that against EBITDA is 5.29.
Stock Price History:
Over the past 52 weeks, COLL has reached a high of $39.90, while it has fallen to a 52-week low of $20.83. The 50-Day Moving Average of the stock is 34.82, while the 200-Day Moving Average is calculated to be 26.75.
Shares Statistics:
COLL traded an average of 450.72K shares per day over the past three months and 656.73k shares per day over the past ten days. A total of 31.87M shares are outstanding, with a floating share count of 30.58M. Insiders hold about 4.32% of the company’s shares, while institutions hold 123.82% stake in the company. Shares short for COLL as of Feb 29, 2024 were 6.72M with a Short Ratio of 14.90, compared to 6.76M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 21.01% and a Short% of Float of 25.90%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of $0.75 for the current quarter, with a high estimate of $0.78 and a low estimate of $0.7, while EPS last year was -$0.51. The consensus estimate for the next quarter is $0.69, with high estimates of $0.73 and low estimates of $0.62.
Analysts are recommending an EPS of between $3.25 and $2.6 for the fiscal current year, implying an average EPS of $2.95. EPS for the following year is $3.67, with 4 analysts recommending between $3.85 and $3.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $149.47M to a low estimate of $145.98M. As of the current estimate, Collegium Pharmaceutical Inc’s year-ago sales were $142.39M, an estimated increase of 3.60% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $142.23M, an increase of 2.80% less than the figure of $3.60% in the same quarter last year. There is a high estimate of $145.17M for the next quarter, whereas the lowest estimate is $139.9M.
A total of 6 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $588.4M, while the lowest revenue estimate was $579.5M, resulting in an average revenue estimate of $583.51M. In the same quarter a year ago, actual revenue was $566.77M, up 3.00% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $595.91M in the next fiscal year. The high estimate is $605.76M and the low estimate is $580.3M. The average revenue growth estimate for next year is up 2.10% from the average revenue estimate for this year.
